Vitamin D Supplementation May Impact Neurodegeneration After Clinically Isolated Syndrome

From NeurologyWire

New findings indicate that vitamin D supplementation may impact neurodegeneration and reduce long-term disability after clinically isolated syndrome (CIS), although these results should be replicated in a second study (Eur J Neurol. 2015 Oct 31.) In the phase 2 CIS trial of atorvastatin, investigators evaluated 25-hydroxyvitamin D levels for their ...

Login to read story

Saturday, October 17, 2015

Show last days of articles

Idarucizumab Approved to Reverse Blood-Thinning Effects of D...

From NeurologyWire

The FDA granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emerg...Full story

Friday, October 16, 2015

Dark Chocolate Offers Benefits for Brain Health, Study Sugge...

From NeurologyWire

The numerous purported health benefits of dark chocolate may also encompass the brain, new research suggests. In a study to be presented this week at ...Full story

Thursday, October 15, 2015

New Cerebral Protection System Shows Neurocognitive Benefits...

From NeurologyWire

A new cerebral protection system (CPS) known as Sentinel (Claret Medical) has recently been shown to protect the vast majority of brain regions from r...Full story

Investigational Small-Protein Drug May Prevent Temporal Lobe...

From NeurologyWire

A potential new class of drugs may prevent the development of temporal lobe epilepsy, according to new research published in Neuron (November 4). Work...Full story

Monday, October 12, 2015

Immune Gene Tied to Prevention of Neurodegenerative Diseases

From NeurologyWire

An immune gene may play a protective role against the development of certain forms of dementia and Parkinsons disease, according to new research publi...Full story

Friday, October 09, 2015

Phase 3 Study Results Highlight Efficacy of Daclizumab High-...

From NeurologyWire

Results from a recent Phase 3 study indicate that once-monthly, investigational daclizumab high-yield process (Zinbryta, Biogen/AbbVie) is effective f...Full story

Revance Initiates Phase 2 Trial for Injectable Cervical Dyst...

From NeurologyWire

Revance Therapeutics has initiated patient dosing in a Phase 2 dose-escalating clinical study of RT002, an investigational drug product candidate to t...Full story

Medtronic TYRX Neuro Absorbable Antibacterial Envelope Now A...

From NeurologyWire

The first implants of the TYRX Absorbable Antibacterial Envelope with Medtronic Deep Brain Stimulation (DBS) systems are now available from Medtronic....Full story

FDA Allows Marketing of First Nucleic Acid-based Test to Det...

From NeurologyWire

The FDA has allowed marketing of the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of multiple pathogens that can...Full story

Wednesday, October 07, 2015

Biogen to Present Long-Term Tecfidera Safety and Efficacy Da...

From NeurologyWire

At the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) now underway in Bercelona, Biogen will prese...Full story

Injectable Agent Approved for Schizophrenia

From NeurologyWire

The FDA approved Aristada (aripiprazole lauroxil, Alkermes, Inc.) extended release injection to treat adults with schizophrenia. The approval is based...Full story

Friday, October 02, 2015

New Report Examines Economic Factors of Rising Rates of Alzh...

From NeurologyWire

The number of people with Alzheimers disease is expected to reach nearly 30 million in the Americas by 2050, according to a new report from Alzheimers...Full story

Wednesday, September 30, 2015

Risk of Developing Parkinsons Disease Higher Among Asthma Pa...

From NeurologyWire

Patients with asthma may have an elevated risk of developing Parkinson's disease later in life, according to new data published in a recent edition of...Full story

Tuesday, September 29, 2015

Investigational Biologic Therapy Impresses in Phase III Tria...

From NeurologyWire

Results from the ORATORIO Phase III trial found that Roche's investigational ocrelizumab reduced progression of clinical disability in patients with p...Full story

Monday, September 28, 2015

First Electronic Autoinjector for RRMS Therapy Approved

From NeurologyWire

The FDA approved Betaconnect, the first electronic autoinjector in the treatment of relapsing-remitting multiple sclerosis (RRMS). Betaconnect will be...Full story